AVTX 009
Alternative Names: AVTX-009; FL-101; Fl101; IL-1β antibody - Eli Lilly; LY 2189102Latest Information Update: 02 Jul 2025
At a glance
- Originator Eli Lilly and Company
- Developer Avalo Therapeutics; Eli Lilly and Company; Flame Biosciences
- Class
- Mechanism of Action Immunosuppressants; Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Discontinued Cardiovascular disorders; Non-small cell lung cancer; Rheumatoid arthritis; Type 2 diabetes mellitus
Most Recent Events
- 17 Apr 2013 Discontinued - Phase-I for Cardiovascular disorders in USA (Parenteral)
- 16 Sep 2011 Final efficacy and adverse events data from a phase II trial in Type-2 diabetes mellitus presented at the 47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011)
- 11 Apr 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)